Drug Trial Radar · NCT01622569
Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety
Last checked: Nov 19, 2026Latest source record: Dec 26, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
323
Actual
Start
Nov 19, 2013
Primary completion
Aug 6, 2015
Study completion Oct 1, 2015
Sponsor
- Lead sponsor
- Optinose US Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 19, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to compare the efficacy of intranasal administration of 100, 200, and 400 μg of fluticasone propionate twice a day delivered by the OptiNose device with placebo in subjects with bilateral nasal polyposis. Two co-primary endpoints will be used in the study: reduction of nasal congestion/obstruction symptoms at the end of Week 4 of the double-blind treatment phase measured by the 7 day average instantaneous AM diary symptom scores, and reduction in total polyp grade (sum of scores from both nasal cavities) over the 16 weeks of the double-blind treatment phase as determined by the Lildholdt scale score measured by nasoendoscopy.
Conditions
- Bilateral Nasal Polyposis
Interventions
Fluticasone PropionateDrug
Delivered via Optinose Exhalation Delivery System
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in 7-day Average Instantaneous Morning Diary Congestion/Obstruction SymptomsTime frame: Baseline, Week 4 of the double-blind treatment phase
- Change in Total Polyp GradeTime frame: Baseline, Week 16 of the double-blind treatment phase
Locations
33 sites in 2 countries. Site status is shown where the registry gives one.
SC Clinical Research, Inc.
Tucson, Arizona
Kern Allergy and Medical Research, Inc.
Bakersfield, California
Central California Clinical Research
Fresno, California
Allergy & Asthma Specialists Medical Group
Huntington Beach, California
California Allergy & Asthma Medical Group, Inc.
Los Angeles, California
Choc PSF, AMC, Division of AA & I
Orange, California
California Allergy and Asthma Palmdale
Palmdale, California
Peninsula Research Associates, Inc.
Rolling Hills Estates, California
California Medical Clinic for Headache
Santa Monica, California
Asthma & Allergy Associates, P.C.
Colorado Springs, Colorado
Colorado ENT & Allergy
Colorado Springs, Colorado
Colorado Allergy and Asthma Centers, P.C.
Denver, Colorado
University of South Florida Asthma, Allergy & Immunology
Tampa, Florida
NU Feinberg School of Medicine Depart. of Otolaryngology-Head & Neck Surgery
Chicago, Illinois
Chicago ENT
Chicago, Illinois
Northeast Medical Research Associates, Inc
North Dartmouth, Massachusetts
The Center for Pharmaceutical Research, P.C.
Kansas City, Missouri
Clinical Research Group of Montana, PLLC
Bozeman, Montana
Coastal Ear, Nose and Throat, LLC
Neptune City, New Jersey
Montefiore Medical Center
The Bronx, New York
Cleveland Clinic
Cleveland, Ohio
Optimed Research
Columbus, Ohio
Allergy, Asthma & Clinical Research Center
Oklahoma City, Oklahoma
Vital Prospects Clinical Research Institute
Tulsa, Oklahoma
National Allergy, Asthma & Urticaria Centers of Charleston, P.A.
North Charleston, South Carolina
AARA Research Center
Dallas, Texas
Ear Nose and Throat Associates of Texas
Frisco, Texas
ENTTEX
Plano, Texas
EVMS Depart. Of Otolaryngology
Norfolk, Virginia
Allergy, Asthma & Sinus Center, S.C.
Greenfield, Wisconsin
Ottawa Allergy Research Corporation
Ottawa, Ontario, Canada
CHUM Hôtel-Dieu
Montreal, Quebec, Canada
Dr. Jaime Del Carpio
Montreal, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.